1. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565
2. Bissery M, Mathieu-Boue A, Lavelle F (1991) Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 32: 402
3. Chabner BA, Myers E (1989) Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Helmann S, Rosenberg A (eds) Cancer Principles & Practice of Oncology. J.B. Lippincott, Philadelphia, pp 349?395
4. Creasey WA, Richards M, Tsou K (1983) Action of (S)-10-hydroxycamptothecin on P388 leukemia and distribution of the drug in mice. Cancer Treat Rep 67: 179
5. Creaven P, Allen L, Muggia F (1972) Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573